Pharmacoeconomic review report Letermovir (Prevymis) (Merck Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource (42 pages) : illustrations

Edition:

Final pharmacoeconomic review report.

Place of Publication:

Ottawa (ON) : CADTH, 2018.

Summary:

Letermovir is an antiviral agent that can be administered orally or intravenously at a dosage of 480 mg daily (or 240 mg daily if co-administered with cyclosporine A) in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) as prophylaxis of cytomegalovirus (CMV) infection. The recommended treatment regimen, as per the Health Canada-approved product monograph, is initiation of letermovir on the day of HSCT or up to 28 days post-transplant and continued through 100 days post-HSCT. At the manufacturer's submitted price (251.28 for the oral formulations and the 240 mg intravenous [IV] vial, 493.78 for the 480 mg IV vial), the average daily drug cost ranges from 251.28 to 493.78. The average cost per treatment, assuming a treatment course of 100 days, ranges from 25,128 to 49,378 per patient. The manufacturer submitted a cost-utility analysis comparing letermovir as prophylaxis of CMV infection, taken alongside usual care, in adult (50.8 years old) CMV-seropositive HSCT recipients compared with usual care alone.

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's Pharmacoeconomic Submission

Manufacturer's Base Case

Summary of Manufacturer's Sensitivity Analyses

Limitations of Manufacturer's Submission

CADTH Common Drug Review Reanalyses

Issues for Consideration

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Summary of Key Outcomes

Appendix 3. Additional Information

Appendix 4. Summary of Other Health Technology Assessment Reviews of Drug

Appendix 5. Reviewer Worksheets

References.

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.